Source link : https://www.newshealth.biz/health-news/upadacitinib-shows-long-term-benefits-in-teens-with-atopic-dermatitis/
Treatment with the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) showed a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, an analysis of three phase III randomized trials showed. At week 76 in the Measure Up 1, Measure Up 2, and AD Up trials, 84-89% of adolescents taking upadacitinib […]
Author : News Health
Publish date : 2024-10-25 19:49:08
Copyright for syndicated content belongs to the linked Source.